Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338924 | 1.00 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Zinc Ion SCHEMBL27625458 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Potassium Ion SCHEMBL2046322 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Potassium Ion SCHEMBL2046315 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL11757302 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL11212645 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL11757313 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| SCHEMBL11212647 | 0.98 | LPAR3 (0.62) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Ether SCHEMBL7120700 | 0.93 | LPAR3 (0.58) | LPAR3LPAR2LPAR1LMNAESR1 | |
| Ether SCHEMBL7124253 | 0.92 | LPAR3 (0.57) | LPAR3LPAR2LPAR1LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 691 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-02-13 | — | — | US | claimed |
| US-20240382504-A1 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-11-21 | — | — | US | claimed |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | claimed |
| EP-4277951-A1 | PHENOL FORMALDEHYDE RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2023-11-22 | — | — | EP | claimed |
| EP-4277952-A1 | AMINOPLAST RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2023-11-22 | — | — | EP | claimed |
| WO-2022152946-A1 | PHENOL FORMALDEHYDE RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2022-07-21 | — | — | WO | claimed |
| WO-2022152901-A1 | AMINOPLAST RESIN FORMULATION AND ADHESIVE FOR CURTAIN COATING | FORESA TECHNOLOGIES, S.L.U. (ES) | 2022-07-21 | — | — | WO | claimed |
| US-20190099342-A1 | COOLING PRODUCT | SYMRISE AG (DE) | 2019-04-04 | — | — | US | claimed |
| EP-2229158-A1 | COMPRESSED CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| EP-2229156-A1 | CHEWING GUM TABLET AND METHOD OF DOSING PHARMACEUTICALLY ACTIVE INGREDIENTS IN SUCH CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| EP-2229157-A1 | COMPRESSED CHEWING GUM TABLET | Fertin Pharma A/S (DK) | 2010-09-22 | — | — | EP | claimed |
| WO-2009080021-A1 | COMPRESSED CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080022-A1 | COMPRESSED CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| WO-2009080020-A1 | CHEWING GUM TABLET AND METHOD OF DOSING PHARMACEUTICALLY ACTIVE INGREDIENTS IN SUCH CHEWING GUM TABLET | FERTIN PHARMA A/S (DK) | 2009-07-02 | — | — | WO | claimed |
| US-5858266-A | CONTAINING A HYDROFLUOROCARBON, A PHOSPHOROUS COMPOUND AND AN OXYGEN-CONTAINING ORGANIC COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 1999-01-12 | — | — | US | claimed |
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| US-4128483-A | Sulfur-containing complex esters and spin finishing compositions using said esters | NIPPON OIL AND FATS CO. LTD. (JP) | 1978-12-05 | — | — | US | disclosed |
| US-4063000-A | Process for production of ferromagnetic powder | FUJI PHOTO FILM CO., LTD. (JA) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382504-A1 | TREATMENT OF SKIN CONDITIONS USING HIGH KRAFFT TEMPERATURE ANIONIC SURFACTANTS | CUTA, LIPA, CETP | ADORA3 2516/4885LPAR3 203/4885LPAR2 269/4885 |
| US-20190099342-A1 | COOLING PRODUCT | TRPA1, TRPV2, NISCH | ADORA3 2852/4885LPAR3 3783/4885LPAR2 3083/4885 |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | PDE12, PDE4A, SMPD4 | ADORA3 2845/4885LPAR3 1226/4885LPAR2 1438/4885 |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | ADORA3 2845/4885LPAR3 1226/4885LPAR2 1438/4885 |
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | ADORA3 2845/4885LPAR3 1226/4885LPAR2 1438/4885 |
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, SMPD4, PDE4A | ADORA3 2059/4885LPAR3 2354/4885LPAR2 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.